(Q53581736)

15 May 2018

title

Current treatment options for malignant peripheral nerve sheath tumors. (English)

1 reference

15 May 2018

author name string

Diana Bradford

series ordinal

1

1 reference

15 May 2018

AeRang Kim

series ordinal

2

1 reference

15 May 2018

publication date

1 March 2015

1 reference

15 May 2018

Current Treatment Options in Oncology

published in

1 reference

15 May 2018

volume

16

1 reference

15 May 2018

issue

3

1 reference

15 May 2018

page(s)

328

1 reference

15 May 2018

Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

Malignant peripheral nerve sheath tumours in neurofibromatosis 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

NF1 tumor suppressor gene function: narrowing the GAP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

TORC1 is essential for NF1-associated malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

Gene expression profiling reveals unique molecular subtypes of Neurofibromatosis Type I-associated and sporadic malignant peripheral nerve sheath tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

Genomic changes in chromosomes 10, 16, and X in malignant peripheral nerve sheath tumors identify a high-risk patient group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

[18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

Utility of 18 FDG positon emission tomography in detection of sarcomatous transformation in neurofibromatosis type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

Value of PET in the assessment of patients with neurofibromatosis type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

Combined-modality treatment of localized soft tissue sarcomas of the extremities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

Malignant peripheral nerve sheath tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

Radiation therapy in management of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

Mouse tumor model for neurofibromatosis type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

Mouse models of tumor development in neurofibromatosis type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

Principles of cancer therapy: oncogene and non-oncogene addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

Postoperative Nomogram for 12-Year Sarcoma-Specific Death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0328-6

Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model.

21 January 2018

1 reference

12 December 2020

Postoperative nomogram for 12-year sarcoma-specific death

1 reference

12 December 2020

Identification of genes potentially involved in the increased risk of malignancy in NF1-microdeleted patients.

1 reference

12 December 2020

Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities

1 reference

12 December 2020

International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis.

1 reference

12 December 2020

Pediatric Malignant Peripheral Nerve Sheath Tumor: The Italian and German Soft Tissue Sarcoma Cooperative Group

1 reference

12 December 2020

Malignant peripheral nerve sheath tumor: analysis of treatment outcome

1 reference

12 December 2020

Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity

1 reference

12 December 2020

Treatment of children with neurogenic sarcoma. Experience at the Children's Hospital of Philadelphia, 1958-1984

1 reference

12 December 2020

10.1007/S11864-015-0328-6

Identifiers

DOI

1 reference

15 May 2018

1 reference

15 May 2018